Robert Lim
Impact in
- Oncology top 0.5%
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Cancer Research top 2%
- Cancer Genomics and Diagnostics
Papers in
- Oncology 30
- Colorectal Cancer Treatments and Studies 23
- Cancer Treatment and Pharmacology 6
-
- Renal cell carcinoma treatment 6
- Gastric Cancer Management and Outcomes 6
- Lung Cancer Treatments and Mutations 6
- Prostate Cancer Treatment and Research 5
- Co-authors
- Arié Figer (3 shared papers)H. Au (2 shared papers)Steven Gallinger (2 shared papers)Robert A. Wolff (2 shared papers)Malcolm J. Moore (2 shared papers)P. Murawa (2 shared papers)Gary M. Clark (2 shared papers)Keyue Ding (2 shared papers)
In The Last Decade
Robert Lim
54 papers receiving 4.4k citations
Robert Lim's Hit Papers
Peers
Comparison fields: 5 of 106
- Oncology 3.1k
- Cancer Research 1.1k
- Pulmonary and Respiratory Medicine 1.4k
- Hepatology 247
- Hematology 340
Countries citing papers authored by Robert Lim
This map shows the geographic impact of Robert Lim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Lim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Lim more than expected).
Fields of papers citing papers by Robert Lim
This network shows the impact of papers produced by Robert Lim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Lim. The network helps show where Robert Lim may publish in the future.
Co-authors
The 25 scholars most cited alongside Robert Lim, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 56 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group Hit paper breakdown → | 2007 | 2909 |
| 2 | 1998 | 425 | |
| 3 | 2013 | 110 | |
| 4 | 2009 | 72 | |
| 5 | 2006 | 66 | |
| 6 | 2010 | 66 | |
| 7 | 2017 | 62 | |
| 8 | 2013 | 56 | |
| 9 | 2017 | 54 | |
| 10 | 1998 | 49 | |
| 11 | 2018 | 48 | |
| 12 | 2020 | 47 | |
| 13 | 2005 | 42 | |
| 14 | 2018 | 38 | |
| 15 | 2016 | 33 | |
| 16 | 2005 | 32 | |
| 17 | 2010 | 31 | |
| 18 | 2007 | 28 | |
| 19 | 2009 | 25 | |
| 20 | 2017 | 25 |
About Robert Lim
Robert Lim is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Pathology and Forensic Medicine and Hepatology, having authored 56 papers that have together received 4.5k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (23 papers), Genetic factors in colorectal cancer (8 papers), Hepatocellular Carcinoma Treatment and Prognosis (7 papers), Cancer Treatment and Pharmacology (6 papers), Renal cell carcinoma treatment (6 papers), Gastric Cancer Management and Outcomes (6 papers), Lung Cancer Treatments and Mutations (6 papers) and Prostate Cancer Treatment and Research (5 papers). The work is most often cited by research in Oncology (3.1k citations), Cancer Research (1.1k citations), Pulmonary and Respiratory Medicine (1.4k citations), Hepatology (247 citations) and Hematology (340 citations). Robert Lim has collaborated with scholars based in Singapore, Canada and China. Frequent co-authors include Arié Figer, H. Au, Steven Gallinger, Robert A. Wolff, Malcolm J. Moore, P. Murawa, Gary M. Clark, Keyue Ding, Daniel de Castro and John Hamm. Their work appears in journals such as Journal of Clinical Oncology, Journal of Magnetic Resonance Imaging, Clinical and Experimental Dermatology, Annals of Oncology and European Radiology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.